natgillin/translations-raw huggingface dataset:
Rasilez may be used alone or in combination with other antihypertensive agents with the exception of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.1).
Rasilez se može primjenjivati sam ili u kombinaciji s drugim antihipertenzivnim lijekovima izuzimajući primjenu u kombinaciji s inhibitorima angiotenzin konvertirajućeg enzima (ACEI) ili blokatorima angiotenzina II receptora (ARB) u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (brzina glomerularne filtracije (GFR) &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.3, 4.4 i 5.1).
RE-SONATE demonstrated dabigatran etexilate was superior to placebo for the prevention of recurrent symptomatic DVT/PE events including unexplained deaths, with a risk reduction from 5.6 % to 0.4 % (relative risk reduction 92 % based on hazard ratio ) during the treatment period (p &lt; 0.0001).
RE-SONATE je pokazao da je dabigatraneteksilat bio superioran placebu u prevenciji rekurentnih simptomatskih događaja DVT/PE-a uključujući neobjašnjene smrti, sa smanjenjem rizika od 5,6% do 0,4% (smanjenje relativnog rizika 92% temeljeno na omjeru hazarda) tijekom razdoblja liječenja (p &lt; 0,0001).
RE-SONATE demonstrated dabigatran etexilate was superior to placebo for the prevention of recurrent symptomatic DVT/PE events including unexplained deaths, with a risk reduction from 5.6 % to 0.4 % (relative risk reduction 92 % based on hazard ratio) during the treatment period (p &lt; 0.0001).
RE-SONATE je pokazao da je dabigatranetekislat bio superioran placebu u prevenciji rekurentnih simptomatskih događaja DVT/PE-a uključujući neobjašnjene smrti, sa smanjenjem rizika s 5,6% na 0,4% (smanjenje relativnog rizika 92% temeljeno na omjera hazarda) tijekom razdoblja liječenja (p &lt; 0,0001).
Reactions occurred rarely ( &lt; 1 in 1,000 injections) between 1 and 3 hours, and very rarely ( &lt; 1 in 10,000 injections) after 3 hours.
Nuspojave su se javljale rijetko ( &lt; 1 na 1000 injekcija) unutar 1-3 sata, a vrlo rijetko ( &lt; 1 na 10 000 injekcija) nakon 3 sata.
Reactions related to volume depletion (including, reports of dehydration, hypovolaemia or hypotension) were reported in 1.1% and 0.7% of subjects who received dapagliflozin 10 mg and placebo, respectively; serious reactions occurred in &lt; 0.2% of subjects balanced between dapagliflozin 10 mg and placebo (see section 4.4).
Reakcije povezane s deplecijom volumena (uključujući prijave dehidracije, hipovolemije ili hipotenzije) prijavljene su u 1,1% ispitanika koji su primali dapagliflozin u dozi od 10 mg i u 0,7% ispitanika koji su primali placebo; ozbiljne reakcije javile su se u &lt; 0,2% ispitanika, podjednako među onima koji su primali dapagliflozin u dozi od 10 mg i onima koji su primali placebo (vidjeti dio 4.4).
Readministration to patients who previously had ASAT or ALAT &gt; 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4)
Ponovna primjena u bolesnika koji su već imali AST ili ALT &gt; 5 x GGN tijekom terapije nevirapinom došlo je do ponovne pojave abnormalnosti jetrene funkcije nakon ponovne primjene nevirapina (vidjeti dio 4.4).
Readministration to patients who previously had ASAT or ALAT &gt; 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4).
Ponovna primjena u bolesnika koji su već imali AST ili ALT &gt; 5 x GGN tijekom terapije nevirapinom došlo do ponovne pojave abnormalnosti jetrene funkcije nakon ponovne primjene nevirapina (vidjeti dio 4.4).
Readministration to patients who previously had ASAT or ALAT &gt; 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine (see section 4.4).
Ponovna primjena u bolesnika koji su već imali AST ili ALT &gt; 5 x GGN tijekom terapije nevirapinom došlo je do ponovne pojave abnormalnosti jetrene funkcije nakon ponovne primjene nevirapina (vidjeti dio 4.4).
Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT ( &gt; 2.5 times ULN).
Primjenu Rebifa treba započeti s oprezom kod bolesnika s povijesti teže bolesti jetre, kliničkih dokaza aktivne bolesti jetre, zlouporabe alkohola ili povišenim vrijednostima ALT-a u serumu ( &gt; 2,5 puta iznad GGN).
recent ( &lt; 10 days) prolonged and vigorous external heart massage
nedavna ( &lt; 10 dana) produžena i intenzivna vanjska masaža srca
Recent findings indicate that exposure in children &lt; 6 years of age may be reduced by about 30 % compared with other age groups.
Najnoviji nalazi upućuju na to da se izloženost u djece ispod 6 godina može smanjiti za otprilike 30% u odnosu na druge starosne skupine.
Recent findings indicate that exposure in children &lt; 6 years of age may be reduced by about 30% compared with other age groups.
Najnoviji nalazi upućuju na to da se izloženost u djece ispod 6 godina može smanjiti za otprilike 30% u odnosu na druge starosne skupine.
Red &amp; Done
CRVENO
Red &amp; Done
Crveno i gotovo
Redness or induration &gt; 2cm in diameter was reported in 22.6 % and 13.9 % of children respectively.
Crvenilo promjera ≥2 cm je zabilježeno u 22,6%, a otvrdnuće promjera ≥2 cm u 13,9% djece.
Redness or induration &gt; 2cm in diameter was reported in 22.6 % and 13.9% of children respectively.
Crvenilo promjera &gt; 2 cm je zabilježeno u 22,6%, a otvrdnuće promjera &gt; 2 cm u 13,9% djece.
Reduced acoustic startle response was observed in juvenile rats 1 – 2 weeks after exposure at &gt; 2 times the human therapeutic exposure.
U mladih je štakora nakon 1-2 tjedna izloženosti &gt; 2 puta većoj od terapijske izloženosti u ljudi opažena umanjena reakcija straha na akustične podražaje.
Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at &gt; 2 times the human therapeutic exposure.
U mladih je štakora nakon 1-2 tjedna izloženosti &gt; 2 puta većoj od terapijske izloženosti u ljudi opažena umanjena reakcija straha na akustične podražaje.
Reduced function can occur as the result of inhibition by interacting medicines (eg ciclosporin) or in patients who are carriers of the SLCO1B1 c.521T &gt; C genotype.
Smanjena funkcija se može pojaviti kao rezultat inhibicije lijekovima koji stupaju u interakciju (npr. ciklosporin) ili u bolesnika koji su nositelji genotipa SLCO1B1 c.521T &gt; C.
Reduction in haemoglobin and platelets were less frequently ( &lt; 5%) reported.
Smanjenje hemoglobina i trombocita zabilježeno je manje često ( &lt; 5%).
Reduction in serum uric acid level to &lt; 6.0 mg/dL (357 µmol/L) was noted by the Week 2 visit and was maintained throughout treatment.
Snižavanje razine mokraćne kiseline u serumu na &lt; 6,0 mg/dl (357 µmol/l) uočena je do kontrole bolesnika nakon 2 tjedna i zadržalo se tijekom cijelog liječenja.
Reductions in LDL-C and changes in other lipid parameters in 13 adolescent patients (aged ≥ 12 to &lt; 18 years) with homozygous familial hypercholesterolaemia are comparable to those in the overall population of patients with homozygous familial hypercholesterolaemia.
Smanjenja vrijednosti LDL-C-a i promjene u drugim lipidnim parametrima u 13 adolescentnih bolesnika (u dobi ≥ 12 do &lt; 18 godina) s homozigotnom obiteljskom hiperkolesterolemijom su usporedive s onima u ukupnoj populaciji bolesnika s homozigotnom obiteljskom hiperkolesterolemijom.
Reductions were 53% (167 to 79 cases) (p &lt; 0.001) for CAP cases with pleural effusion and 63% (64 to 24 cases) (p &lt; 0.001) for microbiologically confirmed pneumococcal CAP cases.
Smanjenja su bila 53% (167 do 79 slučajeva) (p &lt; 0,001) za izvanbolničke slučajeve upale pluća s pleuralnom efuzijom i 63% (64 do 24 slučajeva) (p &lt; 0,001) za mikrobiološki potvrđene slučajeve pneumokoknih izvanbolničkih slučajeva upala pluća.
Refer also to the Summary of Product Characteristics for ribavirin for patients with CrCL &lt; 50 ml/min (see also section 4.2 and 5.2).
Vidjeti također Sažetak opisa svojstava lijeka za ribavirin kod bolesnika s CrCl &lt; 50 ml/min (vidjeti također dijelove 4.2 i 5.2).
Refer also to the Summary of Product Characteristics for ribavirin for patients with CrCl &lt; 50 ml/min.
Za bolesnike s CrCl &lt; 50 ml/min, vidjeti Sažetak opisa svojstava lijeka za ribavirin.
Refer patients with persistent elevations in aminotransferase &gt; 3x ULN to a hepatologist for further investigation.
Bolesnike s trajno povišenim vrijednostima aminotransefaraza &gt; 3 x GGN uputiti hepatologu radi dodatne obrade.
Regadenoson is a low affinity agonist (Ki ≈ 1.3 µM) for the A2A adenosine receptor, with at least 10- fold lower affinity for the A1 adenosine receptor (Ki &gt; 16.5 µM), and very low, if any, affinity for the A2B and A3 adenosine receptors.
Regadenoson je agonist (Ki ≈ 1,3 µM) A2A adenozinskih receptora niskog afiniteta, s najmanje 10 puta nižim afinitetom za A1 adenozinske receptore (Ki &gt; 16,5 µM), i vrlo niskim ili bez afiniteta za A2B i A3 adenozinske receptore.
Regardless of genotype, patients who received IntronA in combination with ribavirin and received  80 % of their treatment had a higher sustained response 6 months after 1 year of treatment than those who took &lt; 80 % of their treatment (56 % vs.
Bez obzira na genotip virusa, bolesnici koji su primali IntronA u kombinaciji s ribavirinom koji su primili ≥ 80% propisane terapije imali su veću stopu trajnog odgovora 6 mjeseci nakon jednogodišnjeg liječenja od kojih koji su primili &lt; 80% propisane terapije (56% u odnosu na 32% bolesnika u ispitivanju
Regardless of whether one or two doses of priming vaccine had been given 6 months earlier, the seroprotection rates against A/Indonesia were &gt; 80% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 and the seroprotection rates against A/Vietnam were &gt; 90% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005.
Neovisno o tome jesu li 6 mjeseci ranije primili jednu ili dvije doze početnog cjepiva, stopa seroprotekcije prema A/Indonesia bila je &gt; 80% nakon doze AS03-adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina dobivenog iz soja A/Vietnam/1194/2004, a stopa seroprotekcije prema A/Vietnam bila je &gt; 90% nakon doze AS03-adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina dobivenog iz soja A/Indonesia/05/2005.
Regardless of whether one or two doses of priming vaccine had been given 6 months earlier, the seroprotection rates against A/Indonesia were &gt; 80% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 and the seroprotection rates against A/Vietnam were &gt; 90% after a dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Indonesia/05/2005.
Neovisno o tome jesu li su prije šest mjeseci primili jednu ili dvije doze primovakcinacije, stopa seroprotekcije protiv A/Indonesia bio je &gt; 80% nakon doze cjepiva s adjuvansom AS03 i 3,75 µg HA dobivenog iz soja A/Vietnam/1194/2004, a stope seroprotekcije protiv A/Vietnam bile su &gt; 90% nakon doze cjepiva s adjuvansom AS03 i 3,75 µg HA dobivenog iz soja A/Indonesia/05/2005.
Regression to normoalbuminuria ( &lt; 30 mg/day) was more frequent in the Aprovel 300 mg group (34%) than in the placebo group (21%).
Regresija do normoalbuminurije ( &lt; 30 mg/dan) bila je češća u skupini koja je primala lijek Aprovel u dozi od 300 mg (34%) nego u skupini koja je primala placebo (21%).
Regression to normoalbuminuria ( &lt; 30 mg/day) was more frequent in the irbesartan 300 mg group (34 %) than in the placebo group (21 %).
Regresija do normoalbuminurije ( &lt; 30 mg/dan) bila je č eš ć a u skupini koja je primala irbesartan 300 mg (34%) nego u skupini koja je primala placebo (21%).
Regression to normoalbuminuria ( &lt; 30 mg/day) was more frequent in the irbesartan 300 mg group (34%) than in the placebo group (21%).
Regresija do normoalbuminurije ( &lt; 30 mg/dan) bila je češća u skupini koja je primala irbesartan 300 mg (34%) nego u skupini koja je primala placebo (21%).
Regression to normoalbuminuria ( &lt; 30 mg/day) was more frequent in the Irbesartan Zentiva 300 mg group (34%) than in the placebo group (21%).
Regresija do normoalbuminurije ( &lt; 30 mg/dan) bila je češća u skupini koja je primala lijek Irbesartan Zentiva u dozi od 300 mg (34%) nego u skupini koja je primala placebo (21%).
Regression to normoalbuminuria ( &lt; 30 mg/day) was more frequent in the Karvea 300 mg group (34%) than in the placebo group (21%).
Regresija do normoalbuminurije ( &lt; 30 mg/dan) bila je češća u skupini koja je primala lijek Karvea u dozi od 300 mg (34%) nego u skupini koja je primala placebo (21%).
Relative to non-obese subjects daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m2) and 42% higher in extremely obese subjects (Body Mass Index of &gt; 40 kg/m2).
U usporedbi s ispitanicima koji nisu bili pretili, sustavna izloženost daptomicinu, mjerena pomoću AUC, bila je za oko 28% veća u umjereno pretilih ispitanika (indeks tjelesne mase 25-40 kg/m2) a 42% veća u ekstremno pretilih ispitanika (indeks tjelesne mase &gt; 40 kg/m2).
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 &lt; 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
Relvar Ellipta je indiciran za simptomatsko liječenje odraslih bolesnika s KOPB-om koji imaju FEV1 &lt; 70% predviđene normalne vrijednosti (nakon primjene bronhodilatatora) i s egzacerbacijama bolesti unatoč redovitom liječenju bronhodilatatorima.
Remains &gt; 33% above pre-treatment average
ostaje &gt; 33% iznad prosjeka prije liječenja
Renal adverse reactions consistent with proximal renal tubulopathy have been reported in HIV-1 infected paediatric patients aged 2 to &lt; 12 years in clinical study GS-US-104-0352 (see sections 4.8 and 5.1).
U kliničkom ispitivanju GS-US-104-0352 u pedijatrijskih su pacijenata zaraženih virusom HIV-1 u dobi od 2 do &lt; 12 godina zabilježene bubrežne nuspojave sukladne proksimalnoj bubrežnoj tubulopatiji (vidjeti dijelove 4.8 i 5.1).
Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine ( &lt; 0.2 % of the radiolabelled dose is parent compound).
Posakonazol se manjim dijelom eliminira putem bubrega, uz 14% radioaktivno označene doze izlučene mokraćom ( &lt; 0,2% radioaktivno označene doze je izvorni spoj).
Renal clearance of metformin hydrochloride is &gt; 400 ml/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metforminklorida je &gt; 400 ml/min što pokazuje da se metforminklorid eliminira putem glomerularne filtracije i tubularne sekrecije.
Renal clearance of metformin is &gt; 400 mL/min indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina je &gt; 400 ml/min, što ukazuje da se metformin eliminira glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 mL/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina je &gt; 400 mL/min i ukazuje na to da se metforminklorid eliminira glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina iznosi &gt; 400 ml/min, što ukazuje na to da se metformin eliminira glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 mL/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina je &gt; 400 ml/min, što ukazuje na to da se eliminira glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina je &gt; 400 ml/min što upućuje da se metformin uklanja glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina veći je od 400 ml/min, što upućuje na to da se metformin eliminira glomerularnom filtracijom i tubularnom sekrecijom.
Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Bubrežni klirens metformina je &gt; 400 ml/min. što ukazuje da se metformin uklanja putem glomerularne filtracije i tubularne sekrecije.
Renal dysfunction: The single-dose pharmacokinetics of nevirapine immediate-release has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
Disfunkcija bubrega: Farmakokinetika jednokratne doze nevirapina s trenutnim oslobađanjem uspoređivana je na 23 bolesnika s blagom (50 ≤ CLcr &lt; 80 ml/min) (n=8), umjerenom (30 ≤ CLcr &lt; 50ml/min), ili teškom (CLcr &lt; 30ml/min) disfunkcijom bubrega, oštećenjem bubrega ili terminalnom bubrežnom insuficijencijom (ESRD) koja zahtijeva dijalizu, te 8 subjekata s urednom bubrežnom funkcijom (CLcr &gt; 80 ml/min).
Renal dysfunction: The single-dose pharmacokinetics of nevirapine immediate-release has been compared in 23 patients with either mild (50  CLcr  80 ml/min), moderate (30  CLcr  50 ml/min) or severe renal dysfunction (CLcr  30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr  80 ml/min).
Disfunkcija bubrega: Farmakokinetika jednokratne doze nevirapina s trenutnim oslobađanjem uspoređivana je na 23 bolesnika s blagom (50 ≤ CLrr &lt; 80 ml/min) (n=8), umjerenom (30 ≤ CLcr &lt; 50ml/min), ili teškom (CLcr &lt; 30ml/min) disfunkcijom bubrega, oštećenjem bubrega ili terminalnom bubrežnom insuficijencijom (ESRD) koja zahtijeva dijalizu, te 8 subjekata s urednom bubrežnom funkcijom (CLcr &gt; 80 ml/min).
Renal excretion of unchanged bedaquiline is insignificant ( &lt; 0.001%).
Izlučivanje nepromijenjenog bedakilina putem bubrega nije značajno ( &lt; 0,001%).
Renal failure due to pyrexia-associated pre-renal azotaemia or granulomatous nephritis was uncommon; however dabrafenib has not been studied in patients with renal insufficiency (defined as creatinine &gt; 1.5 x ULN).
Zatajenja bubrega zbog prerenalne azotemije povezane s pireksijom ili granulomatoznog nefritisa, bila su manje česta; međutim, dabrafenib nije ispitivan u bolesnika s inicijalnom bubrežnom insuficijencijom (definirana kao kreatinin &gt; 1,5 x GGN).
Renal failure has been identified in &lt; 1% of patients treated with dabrafenib alone and in ≤1% of patients treated with dabrafenib in combination with trametinib.
Zatajenje bubrega je utvrđeno u &lt; 1% bolesnika liječenih samo dabrafenibom i u ≤ 1% bolesnika liječenih dabrafenibom u kombinaciji s trametinibom.
Renal failure or renal dysfunction (creatinine clearance &lt; 60 ml/min) (see section 4.4).
zatajenje ili poremećaj funkcije bubrega (klirens kreatinina &lt; 60 ml/min) (vidjeti dio 4.4).
Renal failure or renal dysfunction (creatinine clearance &lt; 60 ml/min).
Zatajenje ili disfunkcija bubrega (klirens kreatinina &lt; 60 ml/min.).
Renal function: Single-dose ribavirin pharmacokinetics were altered (increased AUCtf and Cmax) in patients with renal dysfunction compared with control subjects (creatinine clearance &gt; 90 ml/minute).
Funkcija bubrega: farmakokinetika ribavirina nakon jedne doze bila je izmijenjena (povećani AUCtf i Cmax) u bolesnika s oštećenom funkcijom bubrega u usporedbi s kontrolnim ispitanicima (klirens kreatinina &gt; 90 ml/min).
Renal impairment (eGFR &lt; 60 mL/min/1.73 m2 or CrCl &lt; 60 mL/min)
Oštećenje bubrega (eGFR &lt; 60 mL/min/1,73 m2 ili CrCl &lt; 60 mL/min)
Renal impairment - Compared with patients with normal renal function (creatinine clearance &gt; 80 ml/min), plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min) and on average 2 times lower in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min).
Oštećenje funkcije bubrega - u usporedbi s bolesnicima s normalnom funkcijom bubrega (klirens kreatinina &gt; 80 ml/min), klirens iz plazme je 1,2 do 1,4 puta manji u bolesnika s blagim oštećenjem bubrega (klirens kreatinina 50 do 80 ml/min), a prosječno 2 puta manji u bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30 do 50 ml/min).
Renal impairment: A single 240 mg dose of aprepitant was administered to patients with severe renal impairment (CrCl &lt; 30 mL/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.
Oštećenje funkcije bubrega: Bolesnici s teškim oštećenjem funkcije bubrega (CrCl &lt; 30 ml/min), i bolesnici sa završnim stadijem bolesti bubrega (ESRD-om) na hemodijalizi primili su jednokratnu dozu od 240 mg aprepitanta.
Renal impairment: A single 240 mg dose of oral aprepitant was administered to patients with severe renal impairment (CrCl &lt; 30 ml/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.
Oštećenje funkcije bubrega: Bolesnici s teškim oštećenjem funkcije bubrega (CrCl &lt; 30 ml/min), i bolesnici s bolešću bubrega u terminalnoj fazi (ESRD-om) na hemodijalizi primili su jednokratnu dozu od 240 mg peroralnog aprepitanta.
Renal impairment: a study compared the pharmacokinetics of a single 300 mg dose of maraviroc in subjects with severe renal impairment (CLcr &lt; 30 mL/min, n=6) and end stage renal disease (ESRD) to healthy volunteers (n=6).
Oštećenje bubrega: provedeno je ispitivanje kojim se uspoređivala farmakokinetika jednokratne doze od 300 mg maraviroka u ispitanika s teškim bubrežnim oštećenjem (CLcr &lt; 30 ml/min, n=6) i terminalnim stadijem bubrežne bolesti prema zdravim dobrovoljcima (n=6).
Renal impairment: Adefovir is eliminated by renal excretion and adjustments of the dosing interval are required in patients with a creatinine clearance &lt; 50 ml/min or on dialysis.
Oštećenje funkcije bubrega: Adefovir se eliminira bubrežnim izlučivanjem te su potrebne prilagodbe intervala doziranja u pacijenata s klirensom kreatinina &lt; 50 ml/min ili onih koji su na dijalizi.
Renal impairment: due to the hydrochlorothiazide component, CoAprovel is not recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min).
Oštećenje funkcije bubrega: zbog hidroklorotiazida u sastavu lijeka, CoAprovel se ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina &lt; 30 ml/min.).
Renal impairment: due to the hydrochlorothiazide component, Irbesartan Hydrochlorothiazide Zentiva is not recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min).
Oštećenje funkcije bubrega: zbog hidroklorotiazida u sastavu lijeka, Irbesartan Hydrochlorothiazide Zentiva se ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina &lt; 30 ml/min.).
Renal impairment: due to the hydrochlorothiazide component, Karvezide is not recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min).
Oštećenje funkcije bubrega: zbog hidroklorotiazida u sastavu lijeka, Karvezide se ne preporučuje bolesnicima s teško oštećenom funkcijom bubrega (klirens kreatinina &lt; 30 ml/min.).